BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 16023709)

  • 1. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.
    Di Mascio M; Ribeiro RM; Markowitz M; Ho DD; Perelson AS
    Math Biosci; 2004; 188():47-62. PubMed ID: 14766093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals.
    Lévy Y; Durier C; Lascaux AS; Meiffrédy V; Gahéry-Ségard H; Goujard C; Rouzioux C; Resch M; Guillet JG; Kazatchkine M; Delfraissy JF; Aboulker JP;
    AIDS; 2006 Feb; 20(3):405-13. PubMed ID: 16439874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
    Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
    Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
    Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
    J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic features of HIV-1-infected women on HAART at delivery.
    Ono E; Dos Santos AM; Machado DM; Succi RC; Amed AM; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2008 Jul; 74(4):236-43. PubMed ID: 18393385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.
    Albuquerque AS; Foxall RB; Cortesão CS; Soares RS; Doroana M; Ribeiro A; Lucas M; Antunes F; Victorino RM; Sousa AE
    Clin Immunol; 2007 Oct; 125(1):67-75. PubMed ID: 17692571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
    Weinberg A; Tierney C; Kendall MA; Bosch RJ; Patterson-Bartlett J; Erice A; Hirsch MS; Polsky B;
    J Infect Dis; 2006 Feb; 193(4):488-93. PubMed ID: 16425127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-specific CD4+ T cells and viremia: who's in control?
    Jansen CA; van Baarle D; Miedema F
    Trends Immunol; 2006 Mar; 27(3):119-24. PubMed ID: 16458605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.